Tilray: Fourth Quarter Consensus Estimates

Tilray (TSX: TLRY) (NASDAQ: TLRY) will be reporting its fourth quarter financial results on July 28 before the market opens. Analysts have a consensus $17.77 12-month price target on the company, via a total of 20 analysts, with 2 analysts having strong buy ratings. 3 analysts meanwhile have buy ratings, 14 have hold ratings and a single analyst has a sell rating on the company. The street high comes from Roth Capital with a $25 price target, and the lowest target sits at $1.27 from GLJ Research.

10 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 10 analysts is $146.19 million; this number has been revised upwards from $71.20 million at the start of the year. The highest revenue estimate is $175.4 million, while the lowest is $107.62 million.

Onto EBITDA estimates, there are currently 7 analysts who have fourth-quarter EBITDA estimates. The mean is currently $5.81 million, with this number being flat since the start of the year. The street high estimate currently sits at $11.7 million in EBITDA and the lowest is -$2.83 million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Can the World Actually Supply $6 Copper? | Greg Ferron – PTX Metals

1911 Gold: The Power Of A Mine Restart

Is Gold Repeating the 2005 Setup Before The Big Run? | Geordie Mark

Recommended

Nord Precious Metals Hits Multiple Intervals Of Mineralization In Latest Drill Hole At Castle East

Goliath Resources Sees 13% Grade Boost As Stifel Draws Parallels To Great Bear

Related News

Air Canada: BMO Reinstates Coverage With $33 Price Target

Last week, BMO Capital Markets reinstated their coverage on Air Canada (TSX: AC) after discontinuing...

Saturday, March 6, 2021, 10:17:00 AM

Medipharm Labs: Canaccord Lowers Targets After Earnings

On August 16, Medipharm Labs (TSX: LABS) reported their second quarter financial results. The company...

Friday, August 20, 2021, 07:54:00 AM

Equinox: BMO Lowers Price Target To $14.50 Follow Mercedes Mine Sale

On December 17th, Equinox Gold (TSX: EQX) announced that they reached an agreement to sell...

Tuesday, December 28, 2021, 11:06:00 AM

Topaz Energy Sees BMO Resume Analyst Coverage

On June 8th, Topaz Energy Corp. (TSX: TPZ) had a flurry of news releases. The...

Friday, June 11, 2021, 04:16:00 PM

Valens Sees Canaccord Cut Price Target After Investor Day

On February 7th, The Valens Company (TSX: VLNS) held its 2022 investor day. The company...

Friday, February 11, 2022, 02:54:00 PM